Insider Transactions Reported by 18 Insiders of LeonaBio, Inc.

Symbol
LONA on Nasdaq
Location
Bothell, WA

Quick Takeaways

  • LONA - LeonaBio, Inc. has 18 insiders with reported activity on this page.
  • Net insider value flow over the last year: -$115,829.
  • Recent transaction rows are available for direct filing-level review.

What Changed

  • Buy value: ; sell value: $115,828.
  • Net share flow: -72,662.

Why This Matters

  • This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
  • Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Source Evidence

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Net insider flow leans to selling over the last 12 months. Net value: -$115,829.

Buys

$0

Shares: 0

Insiders: 0

Sells

$115,829

Shares: 72,662

Insiders: 5

Net

-$115,829

Shares: -72,662

Insiders: -5

Window (months) Buy shares Sell shares Buy $ Sell $ Net $
0-3 0 10,469 $0 $56,219 -$56,219
3-6 0 6,279 $0 $43,200 -$43,200
6-9 0 0 $0 $0 $0
9-12 0 55,914 $0 $16,411 -$16,411

LeonaBio, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
PERCEPTIVE ADVISORS LLC Director, 10%+ Owner $17,718,931 Mixed 23 Dec 2025
Mark James Litton PRESIDENT and CEO, Director $445,121 -$52,853 -11% Mixed 09 Apr 2026
Hans Moebius Chief Medical Officer $266,213 Mixed 04 Jan 2024
Kelly A. Romano Director $194,951 Filing P/S 09 Apr 2026
Kevin Church Chief Scientific Officer $168,112 -$15,827 -8.6% Mixed 09 Apr 2026
Mark Worthington GENERAL COUNSEL and CCO $130,855 -$15,661 -11% Mixed 09 Apr 2026
Javier San Martin Chief Medical Officer $126,995 -$23,729 -16% Mixed 09 Apr 2026
Robert Renninger Chief Financial Officer $107,033 -$7,759 -6.8% Mixed 09 Apr 2026
Andrew Gengos CFO and Chief Business Officer $55,203 Filing P/S 03 Sep 2024
Rachel Lenington COO and CDO $11,812 Filing P/S 03 Sep 2024
Glenna Mileson Chief Financial Officer Mixed 19 Jan 2023
Tadataka Yamada Director Mixed 28 May 2021
Barbara Kosacz Director Mixed 09 Apr 2026
Grant Pickering Director Mixed 09 Apr 2026
Michael A. Panzara Director Mixed 09 Apr 2026
Joseph Edelman Director Mixed 09 Apr 2026
John M. Fluke Jr. Director Mixed 09 Apr 2026
James A. Johnson Director Mixed 09 Apr 2026

Top shareholders of LeonaBio, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
PERCEPTIVE ADVISORS LLC
3/4/5 13D/G 13F
Director, 10%+ Owner · Company
20%
from 13D/G
8,292,785
mixed-class rows
$17,718,931 23 Dec 2025
ACORN CAPITAL ADVISORS, LLC
13F
Company
13%
501,739
$3,798,164 31 Dec 2025
13F
Commodore Capital LP
13F
Company
12%
464,398
$3,515,493 31 Dec 2025
13F
NEA Management Company, LLC
13F
Company
12%
464,398
$3,515,493 31 Dec 2025
13F
TCG Crossover Management, LLC
13F
Company
12%
464,398
$3,348,507 31 Dec 2025
13F
Kalehua Capital Management LLC
13F
Company
9.9%
393,701
$2,980,317 31 Dec 2025
13F
Spruce Street Capital LP
13F
Company
9.9%
393,701
$2,980,317 31 Dec 2025
13F
ADAR1 Capital Management, LLC
13F
Company
9.9%
393,701
$2,890,907 31 Dec 2025
13F
MILLENNIUM MANAGEMENT LLC
13F
Company
8.1%
324,445
$2,456,049 31 Dec 2025
13F
ACORN BIOVENTURES, L.P.
13D/G
Anders Hove
6.2%
596,068
$1,345,504 +$212,929 06 Jan 2026
VANGUARD GROUP INC
13F
Company
3.9%
153,789
$1,164,183 31 Dec 2025
13F
Propel Bio Management, LLC
13F
Company
3.7%
149,279
$1,130,042 31 Dec 2025
13F
Simplify Asset Management Inc.
13F
Company
3.7%
149,279
$1,130,042 31 Dec 2025
13F
Seven Fleet Capital Management LP
13F
Company
3.2%
127,951
$968,589 31 Dec 2025
13F
Baselake Partners, LP
13D/G
1.9%
75,789
$573,723 -$921,208 31 Dec 2025
RENAISSANCE TECHNOLOGIES LLC
13F
Company
1.9%
75,147
$568,863 31 Dec 2025
13F
Mark James Litton
3/4/5
PRESIDENT and CEO, Director
mixed-class rows
809,894
mixed-class rows
$445,121 -$52,853 09 Apr 2026
BlackRock, Inc.
13F
Company
0.94%
37,643
$284,958 31 Dec 2025
13F
ACADIAN ASSET MANAGEMENT LLC
13F
Company
0.94%
37,482
$282,000 31 Dec 2025
13F
Pathstone Holdings, LLC
13F
Company
0.97%
38,606
$278,903 31 Dec 2025
13F
Hans Moebius
3/4/5
Chief Medical Officer
class O/S missing
91,482
$266,213 04 Jan 2024
BANK OF AMERICA CORP /DE/
13F
Company
0.82%
32,840
$248,599 31 Dec 2025
13F
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
0.78%
30,944
$234,308 31 Dec 2025
13F
Kelly A. Romano
3/4/5
Director
mixed-class rows
108,715
mixed-class rows
$194,951 09 Apr 2026
Kevin Church
3/4/5
CHIEF SCIENTIFIC OFFICER
mixed-class rows
325,178
mixed-class rows
$168,112 -$15,827 09 Apr 2026
Laird Norton Wetherby Trust Company, LLC
13F
Company
0.55%
21,818
$165,162 31 Dec 2025
13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP
13F
Company
0.52%
20,936
$158,486 31 Dec 2025
13F
Mark Worthington
3/4/5
GENERAL COUNSEL and CCO
mixed-class rows
318,376
mixed-class rows
$130,855 -$15,661 09 Apr 2026
Javier San Martin
3/4/5
CHIEF MEDICAL OFFICER
mixed-class rows
365,887
mixed-class rows
$126,995 -$23,729 09 Apr 2026
Robert Renninger
3/4/5
CHIEF FINANCIAL OFFICER
mixed-class rows
315,851
mixed-class rows
$107,033 -$7,759 09 Apr 2026
JANE STREET GROUP, LLC
13F
Company
0.33%
13,186
$99,818 31 Dec 2025
13F
TWO SIGMA INVESTMENTS, LP
13F
Company
0.27%
10,746
$81,347 31 Dec 2025
13F
STATE STREET CORP
13F
Company
0.27%
10,737
$81,279 31 Dec 2025
13F
NORTHERN TRUST CORP
13F
Company
0.26%
10,461
$79,190 31 Dec 2025
13F
Scientech Research LLC
13F
Company
0.25%
10,108
$76,518 31 Dec 2025
13F
OSAIC HOLDINGS, INC.
13F
Company
0.23%
9,210
$69,719 31 Dec 2025
13F
Steven Michael Oliveira
13D/G
Oliveira Steven Michael
4.1%
161,218
$69,324 -$788,375 01 Oct 2025
Andrew Gengos
3/4/5
CFO and Chief Business Officer
mixed-class rows
377,532
mixed-class rows
$55,203 03 Sep 2024
UBS Group AG
13F
Company
0.08%
3,388
$25,647 31 Dec 2025
13F
Rachel Lenington
3/4/5
COO and CDO
mixed-class rows
320,870
mixed-class rows
$11,812 03 Sep 2024
MORGAN STANLEY
13F
Company
0.01%
470
$3,558 31 Dec 2025
13F
ROYAL BANK OF CANADA
13F
Company
0.01%
334
$3,000 31 Dec 2025
13F
Tower Research Capital LLC (TRC)
13F
Company
0.01%
379
$2,869 31 Dec 2025
13F
American Capital Advisory, LLC
13F
Company
0.01%
200
$1,514 31 Dec 2025
13F
ROTHSCHILD INVESTMENT LLC
13F
Company
0%
150
$1,136 31 Dec 2025
13F
McIlrath & Eck, LLC
13F
Company
0%
82
$621 31 Dec 2025
13F
US BANCORP \DE\
13F
Company
0%
81
$613 31 Dec 2025
13F
GROUP ONE TRADING LLC
13F
Company
0%
69
$522 31 Dec 2025
13F
Global Retirement Partners, LLC
13F
Company
0%
52
$393 31 Dec 2025
13F
NewEdge Advisors, LLC
13F
Company
0%
50
$378 31 Dec 2025
13F

Recent Insider Transactions by Companies or Individuals for LeonaBio, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
Michael A. Panzara LONA Stock Option (Right to Buy) Award 28,000 28,000 09 Apr 2026 Direct
Kevin Church LONA Stock Option (Right to Buy) Award 300,000 300,000 09 Apr 2026 Direct
Barbara Kosacz LONA Stock Option (Right to Buy) Award 28,000 28,000 09 Apr 2026 Direct
Grant Pickering LONA Stock Option (Right to Buy) Award 28,000 28,000 09 Apr 2026 Direct
Kelly A. Romano LONA Stock Option (Right to Buy) Award 28,000 28,000 09 Apr 2026 Direct
James A. Johnson LONA Stock Option (Right to Buy) Award 28,000 28,000 09 Apr 2026 Direct
Joseph Edelman LONA Stock Option (Right to Buy) Award 28,000 28,000 09 Apr 2026 Direct
Javier San Martin LONA Stock Option (Right to Buy) Award 350,000 350,000 09 Apr 2026 Direct
John M. Fluke Jr. LONA Stock Option (Right to Buy) Award 28,000 28,000 09 Apr 2026 Direct
Mark Worthington LONA Stock Option (Right to Buy) Award 300,000 300,000 09 Apr 2026 Direct
Robert Renninger LONA Stock Option (Right to Buy) Award 300,000 300,000 09 Apr 2026 Direct
Mark James Litton LONA Stock Option (Right to Buy) Award 750,000 750,000 09 Apr 2026 Direct
Mark James Litton LONA Common Stock Sale -8.17% $27,688 $5.37 -5,156 57,926 04 Mar 2026 Direct
Robert Renninger LONA Common Stock Sale -5.41% $4,865 $5.37 -906 15,851 04 Mar 2026 Direct
Mark Worthington LONA Common Stock Sale -6.74% $7,131 $5.37 -1,328 18,376 04 Mar 2026 Direct
Kevin Church LONA Common Stock Sale -5.12% $7,298 $5.37 -1,359 25,178 04 Mar 2026 Direct
Javier San Martin LONA Common Stock Sale -9.77% $9,236 $5.37 -1,720 15,887 04 Mar 2026 Direct
Mark James Litton LONA Common Stock Options Exercise 54.5% 22,254 63,082 03 Mar 2026 Direct
Mark James Litton LONA Restricted Stock Units Options Exercise -100% -22,254 0 03 Mar 2026 Direct
Robert Renninger LONA Common Stock Options Exercise 30.3% 3,900 16,757 03 Mar 2026 Direct
Robert Renninger LONA Restricted Stock Units Options Exercise -100% -3,900 0 03 Mar 2026 Direct
Mark Worthington LONA Common Stock Options Exercise 41% 5,726 19,704 03 Mar 2026 Direct
Mark Worthington LONA Restricted Stock Units Options Exercise -100% -5,726 0 03 Mar 2026 Direct
Kevin Church LONA Common Stock Options Exercise 28.3% 5,856 26,537 03 Mar 2026 Direct
Kevin Church LONA Restricted Stock Units Options Exercise -100% -5,856 0 03 Mar 2026 Direct
Javier San Martin LONA Common Stock Options Exercise 72.8% 7,418 17,607 03 Mar 2026 Direct
Javier San Martin LONA Restricted Stock Units Options Exercise -100% -7,418 0 03 Mar 2026 Direct
Javier San Martin ATHA Common Stock Sale -13.9% $11,311 $6.88 -1,644 10,189 02 Jan 2026 Direct
Mark James Litton ATHA Common Stock Sale -5.96% $17,792 $6.88 -2,586 40,828 02 Jan 2026 Direct
Robert Renninger ATHA Common Stock Sale -2.26% $2,043 $6.88 -297 12,857 02 Jan 2026 Direct
Kevin Church ATHA Common Stock Sale -4.06% $6,027 $6.88 -876 20,681 02 Jan 2026 Direct
Mark Worthington ATHA Common Stock Sale -5.9% $6,027 $6.88 -876 13,978 02 Jan 2026 Direct
Javier San Martin ATHA Common Stock Options Exercise 65.1% 4,667 11,833 31 Dec 2025 Direct
Javier San Martin ATHA Restricted Stock Units Options Exercise -100% -4,667 0 31 Dec 2025 Direct
Mark James Litton ATHA Common Stock Options Exercise 33.2% 10,834 43,414 31 Dec 2025 Direct
Mark James Litton ATHA Restricted Stock Units Options Exercise -100% -10,834 0 31 Dec 2025 Direct
Robert Renninger ATHA Common Stock Options Exercise 10.4% 1,236 13,154 31 Dec 2025 Direct
Robert Renninger ATHA Restricted Stock Units Options Exercise -100% -1,236 0 31 Dec 2025 Direct
Kevin Church ATHA Common Stock Options Exercise 20.5% 3,667 21,557 31 Dec 2025 Direct
Kevin Church ATHA Restricted Stock Units Options Exercise -100% -3,667 0 31 Dec 2025 Direct
Mark Worthington ATHA Common Stock Options Exercise 32.8% 3,667 14,854 31 Dec 2025 Direct
Mark Worthington ATHA Restricted Stock Units Options Exercise -100% -3,667 0 31 Dec 2025 Direct
Robert Renninger ATHA Stock Option (Right to Buy) Award 34,358 34,358 24 Dec 2025 Direct
Mark James Litton ATHA Stock Option (Right to Buy) Award 133,526 133,526 24 Dec 2025 Direct
Kevin Church ATHA Stock Option (Right to Buy) Award 35,138 35,138 24 Dec 2025 Direct
Javier San Martin ATHA Stock Option (Right to Buy) Award 44,508 44,508 24 Dec 2025 Direct
Mark Worthington ATHA Stock Option (Right to Buy) Award 34,358 34,358 24 Dec 2025 Direct
Perceptive Advisors Llc ATHA Common Stock Award 626.5% 1,319,026 1,529,566 23 Dec 2025 See Footnotes
Perceptive Advisors Llc ATHA Series B Warrant (right to buy) Award 4,724,408 3,543,307 23 Dec 2025 See Footnotes
Perceptive Advisors Llc ATHA Series A Warrant (right to buy) Award 5,118,109 3,838,583 23 Dec 2025 See Footnotes
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .